FisclearFisclear

Financial Comparison

Cipla Limited vs Dr. Reddy's Laboratories Limited

Click a ticker to view the full analysis.

CIPLA.NS vs

In short

Cipla Limited is the more profitable of the two, keeping 14.0% of revenue as net profit against 12.8% for Dr. Reddy's Laboratories Limited. Cipla Limited trades at the higher trailing P/E (31.9× vs 30.5× for Dr. Reddy's Laboratories Limited), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for Cipla Limited and 0 for Dr. Reddy's Laboratories Limited.

Based on filings for periods ending 31 Mar 2026 (CIPLA.NS) and 31 Mar 2026 (DRREDDY.NS) · Updated

FisclearScore Comparison

CIPLA.NS51Fair
DRREDDY.NS55Fair
Quality+6
89
83
Efficiency
47
47
Value
26
26
Cashflow+38
25
63
Regime
55
55
Peers+7
58
51

FisclearScore is a quantitative model. CIPLA.NS shown solid · DRREDDY.NS shown dashed. Not financial advice.

MetricCIPLA.NSDRREDDY.NS
Price₹1,310.50₹1,188.00
Market Cap₹1.06T₹989.6B
P/E (TTM)31.9x30.5x
P/B3.1x2.6x
Beta0.090.25
Div Yield0.99%0.65%
Revenue (TTM)₹277.1B₹335.9B
Net Income₹38.8B₹42.9B
Gross Margin62.3%52.8%
Risk Flags—1 flag
Full CIPLA.NS Report →Full DRREDDY.NS Report →

Related comparisons

Dr. Reddy's Laboratories vs Sun PharmaceuticalCIPLA.NS vs Sun PharmaceuticalDIVISLAB.NS vs Dr. Reddy's LaboratoriesAPOLLOHOSP.NS vs Dr. Reddy's LaboratoriesDr. Reddy's Laboratories vs TORNTPHARM.NSCIPLA.NS vs DIVISLAB.NS

Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.